Notable Runner: Hologic Inc Stock Increased as Institutional Investors Enter

November 29, 2016 - By Dolores Ford   ·   0 Comments

Notable Runner: Hologic Inc Stock Increased as Institutional Investors Enter

Sentiment for Hologic Inc (NASDAQ:HOLX)

Hologic Inc (NASDAQ:HOLX) institutional sentiment increased to 1.24 in Q2 2016. Its up 0.22, from 1.02 in 2016Q1. The ratio increased, as 203 active investment managers opened new and increased equity positions, while 199 sold and reduced equity positions in Hologic Inc. The active investment managers in our partner’s database now hold: 258.39 million shares, up from 252.92 million shares in 2016Q1. Also, the number of active investment managers holding Hologic Inc in their top 10 equity positions was flat from 5 to 5 for the same number . Sold All: 52 Reduced: 147 Increased: 150 New Position: 53.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The company has a market cap of $10.79 billion. The Firm operates through four divisions: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. It has a 33.44 P/E ratio. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

The stock decreased 0.97% or $0.38 during the last trading session, hitting $38.68. Hologic, Inc. (NASDAQ:HOLX) has risen 2.60% since April 26, 2016 and is uptrending. It has underperformed by 2.66% the S&P500.

Analysts await Hologic, Inc. (NASDAQ:HOLX) to report earnings on January, 25. They expect $0.50 earnings per share, up 8.70% or $0.04 from last year’s $0.46 per share. HOLX’s profit will be $139.48M for 19.34 P/E if the $0.50 EPS becomes a reality. After $0.52 actual earnings per share reported by Hologic, Inc. for the previous quarter, Wall Street now forecasts -3.85% negative EPS growth.

According to Zacks Investment Research, “Hologic Inc. is a leading supplier of high quality, innovative and clinically valuable diagnostic systems and tests. The company develops, manufactures and markets X-ray bone densitometers and ultrasound bone analyzers that address a growing market for osteoporosis prevention and treatment — a key element of women’s health care. The systems are used by more leading medical schools, universities and osteoporosis opinion leaders than any other bone densitometer.”

Healthcor Management L.P. holds 7.55% of its portfolio in Hologic, Inc. for 4.00 million shares. Lateef Investment Management L.P. owns 4.64 million shares or 5.45% of their US portfolio. Moreover, Nine Chapters Capital Management Llc has 4.41% invested in the company for 6,100 shares. The United Kingdom-based Arrowgrass Capital Partners Llp has invested 2.55% in the stock. Malaga Cove Capital Llc, a California-based fund reported 70,100 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 9 sales for $3.33 million net activity.

Hologic, Inc. (NASDAQ:HOLX) Ratings Coverage

Ratings analysis reveals 78% of Hologic’s analysts are positive. Out of 9 Wall Street analysts rating Hologic, 7 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $40 while the high is $52. The stock’s average target of $45.50 is 17.63% above today’s ($38.68) share price. HOLX was included in 14 notes of analysts from July 24, 2015. The firm earned “Hold” rating on Thursday, April 28 by Needham. The stock of Hologic, Inc. (NASDAQ:HOLX) has “Buy” rating given on Monday, October 26 by BTIG Research. Craig Hallum downgraded the shares of HOLX in a report on Wednesday, October 21 to “Hold” rating. The firm has “Buy” rating given on Monday, August 3 by Argus Research. The firm has “Equal Weight” rating given on Wednesday, September 2 by Barclays Capital. Jefferies maintained Hologic, Inc. (NASDAQ:HOLX) rating on Friday, September 18. Jefferies has “Buy” rating and $48 price target. The rating was maintained by Barclays Capital on Thursday, July 30 with “Underweight”. Gabelli initiated Hologic, Inc. (NASDAQ:HOLX) rating on Monday, October 26. Gabelli has “Buy” rating and $43 price target. As per Friday, July 24, the company rating was initiated by Bank of America. The company was upgraded on Friday, September 23 by Barclays Capital.

HOLX Company Profile

Hologic, Inc., incorporated on January 18, 1990, is a developer, maker and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Firm operates through four divisions: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Firm sells and services its products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives. The Firm offers a range of diagnostic products, which are used to aid in the diagnosis of human diseases and screen donated human blood and plasma.

More news for Hologic, Inc. (NASDAQ:HOLX) were recently published by: Prnewswire.com, which released: “Hologic Announces Upcoming Put Option and Notice of Redemption of 2.00 …” on November 09, 2016. Prnewswire.com‘s article titled: “Hologic Announces Financial Results for Fourth Quarter of Fiscal 2016” and published on November 02, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>